ATE394376T1 - Tetrahydrochinolinderivatverbindung und die verbindung als wirkstoff enthaltendes arzneimittel - Google Patents
Tetrahydrochinolinderivatverbindung und die verbindung als wirkstoff enthaltendes arzneimittelInfo
- Publication number
- ATE394376T1 ATE394376T1 AT02738734T AT02738734T ATE394376T1 AT E394376 T1 ATE394376 T1 AT E394376T1 AT 02738734 T AT02738734 T AT 02738734T AT 02738734 T AT02738734 T AT 02738734T AT E394376 T1 ATE394376 T1 AT E394376T1
- Authority
- AT
- Austria
- Prior art keywords
- ppar
- compound
- agonist
- alkyl
- activity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001184068 | 2001-06-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE394376T1 true ATE394376T1 (de) | 2008-05-15 |
Family
ID=19023903
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02738734T ATE394376T1 (de) | 2001-06-18 | 2002-06-17 | Tetrahydrochinolinderivatverbindung und die verbindung als wirkstoff enthaltendes arzneimittel |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US6924295B2 (de) |
| EP (1) | EP1405848B1 (de) |
| JP (1) | JPWO2002102780A1 (de) |
| AT (1) | ATE394376T1 (de) |
| DE (1) | DE60226441D1 (de) |
| WO (1) | WO2002102780A1 (de) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6867224B2 (en) * | 2002-03-07 | 2005-03-15 | Warner-Lambert Company | Compounds that modulate PPAR activity and methods of preparation |
| US6833380B2 (en) | 2002-03-07 | 2004-12-21 | Warner-Lambert Company, Llc | Compounds that modulate PPAR activity and methods of preparation |
| EP1581491A1 (de) * | 2003-01-06 | 2005-10-05 | Eli Lilly And Company | Indolderivate als ppar-modulatoren |
| JP2005104951A (ja) * | 2003-01-17 | 2005-04-21 | Kirin Brewery Co Ltd | 血圧降下用組成物および血管柔軟性改善用組成物並びにこれらの機能が付与された食品 |
| PA8594401A1 (es) * | 2003-02-21 | 2004-09-16 | Pfizer | Acidos carboxilicos de heteroarilo condensado como agonista del ppar |
| US7244763B2 (en) | 2003-04-17 | 2007-07-17 | Warner Lambert Company Llc | Compounds that modulate PPAR activity and methods of preparation |
| BRPI0412236A (pt) * | 2003-07-02 | 2006-09-12 | Hoffmann La Roche | compostos, processo para a sua manufatura, composições farmacêuticas que compreendem os mesmos, método para o tratamento e/ou prevenção de enfermidades que são moduladas por agonistas ppar(delta) e/ou ppar(alfa), e utilização desses compostos |
| US20080125403A1 (en) | 2004-04-02 | 2008-05-29 | Merck & Co., Inc. | Method of Treating Men with Metabolic and Anthropometric Disorders |
| EP1887000A4 (de) * | 2005-05-27 | 2011-09-07 | Shionogi & Co | Arylacetatderivat mit isoxazolgerüst |
| CN101622234B (zh) * | 2007-03-06 | 2013-08-07 | 诺瓦提斯公司 | 适于治疗炎性或变应性病症的二环有机化合物 |
| JP5718233B2 (ja) | 2008-10-20 | 2015-05-13 | ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 甲状腺刺激ホルモン受容体（ｔｓｈｒ）の低分子量アゴニスト |
| JP5965387B2 (ja) | 2010-04-08 | 2016-08-03 | アメリカ合衆国 | Ｔｓｈ受容体用のインバースアゴニストおよびニュートラルアンタゴニスト |
| WO2012027331A1 (en) | 2010-08-27 | 2012-03-01 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0885205A4 (de) * | 1996-02-28 | 2002-11-27 | Merck & Co Inc | Fibrinogen-rezeptor-antagonisten |
| US5780480A (en) * | 1996-02-28 | 1998-07-14 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
| CA2259431A1 (en) * | 1996-07-01 | 1998-01-08 | Eli Lilly And Company | Hypoglycemic and hypolipidemic compounds |
| DE69722234T2 (de) * | 1996-10-09 | 2004-04-01 | Sumitomo Chemical Co., Ltd. | Verfahren zur reinigung von brenztraubensäureverbindungen |
| AU9002798A (en) | 1997-09-19 | 1999-04-12 | Ono Pharmaceutical Co. Ltd. | Fused or nonfused benzene compounds |
| EP1108713A4 (de) | 1998-08-27 | 2006-04-05 | Ono Pharmaceutical Co | Carbonsäurederivate und sie als aktiven bestandteil enthaltende medikamente |
-
2002
- 2002-06-17 AT AT02738734T patent/ATE394376T1/de not_active IP Right Cessation
- 2002-06-17 WO PCT/JP2002/006005 patent/WO2002102780A1/ja not_active Ceased
- 2002-06-17 JP JP2003505322A patent/JPWO2002102780A1/ja not_active Withdrawn
- 2002-06-17 EP EP02738734A patent/EP1405848B1/de not_active Expired - Lifetime
- 2002-06-17 US US10/481,103 patent/US6924295B2/en not_active Expired - Fee Related
- 2002-06-17 DE DE60226441T patent/DE60226441D1/de not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1405848B1 (de) | 2008-05-07 |
| EP1405848A1 (de) | 2004-04-07 |
| US6924295B2 (en) | 2005-08-02 |
| EP1405848A4 (de) | 2007-03-21 |
| WO2002102780A1 (en) | 2002-12-27 |
| DE60226441D1 (de) | 2008-06-19 |
| JPWO2002102780A1 (ja) | 2004-09-30 |
| US20040171835A1 (en) | 2004-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60226441D1 (de) | Tetrahydrochinolinderivatverbindung und die verbindung als wirkstoff enthaltendes arzneimittel | |
| DE60018064D1 (de) | Substituierte phenylpropionsäurederivate als agonisten des menschlichen peroxisom-proliferator-aktiverten rezeptors alpha(ppar) | |
| FR2890071B1 (fr) | Nouveaux composes de l'indole | |
| RU2009127302A (ru) | Способ изготовления твердого, орально применимого фармацевтического состава | |
| NO20034986D0 (no) | Furan og tiofenderivater som aktiverer human peroksisom proliferator aktiverte reseptorer | |
| HUP9902808A2 (hu) | 5-(2-(4-(1,2-Benzizotiazol-3-il)-1-piperazinil)-etil)-6-klór-1,3-dihidro-2-(1H)-indol-2-on (ziprazidon) mezilát-trihidrát sói, a vegyületek előállítása és dopamin D2 antagonistaként történő alkalmazása | |
| DE60110262D1 (de) | Thiazol und oxazol-derivate als aktivatoren von menschlichen peroxisom proliferator aktivierten rezeptoren | |
| TNSN08091A1 (fr) | Derives de pyrrolopyridine et leurs utilisations comme modulateurs des recepteurs ppar | |
| NL980008I1 (nl) | Gebruik van sertindool voor de behandeling van schizofrenie. | |
| AU2001284658A1 (en) | Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists | |
| CL2009001310A1 (es) | Compuesto intermediario (2-clorofenil)-[2-(2-hidroxi-2-piridin-4-ilvinil)piridin-3-il]metanona o una sal del mismo en lapreparacion del compuesto {2-[1-(3,5-bistrifluorometilbencil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]piridin-3-il}-(2-cloofenil)metanona (div. sol. 2680-04). | |
| EP1078923A3 (de) | Verfahren zur Herstellung von Benzothiophen-Derivaten | |
| ATE228119T1 (de) | Heterocyclische carboxamide | |
| AR037164A1 (es) | Metodo de tratamiento. | |
| ES8602652A1 (es) | Procedimiento para la preparacion de n-piridilindoles | |
| HN1996000086A (es) | Producto de proteccion de cultivos | |
| FR2865732B1 (fr) | Composes de type hydrazide et leur utilisation dans des compositions pharmaceutiques pour le traitement des maladies cardiovasculaires | |
| MXPA04000775A (es) | Uso novedoso del 2 -[5-(4-fluorofenil) -3-piridilmetilamino-metil] -cromano y sus sales fisiologicamente aceptables. | |
| ATE234098T1 (de) | 4-aminopyrrole (3,2-d) pyrimidinen als antagonisten des neuropeptide y receptors | |
| PT1446404E (pt) | Edisilatos de rosiglitazona e sua utilizacao como antidiabeticos | |
| DK0532177T3 (da) | Methanoanthracener som dopaminantagonister | |
| AP1715A (en) | The hydrochloride salt of 5-[ 4 -[2 -(n-methyl-n- (2-pyridyl) amino) ethoxy]benzyl]thiazolidine -2,4-dione | |
| UA95601C2 (ru) | Метансульфонат этилового эфира 3-[(2-{[4-(гексилоксикарбониламиноиминометил)фениламино]метил}-1метил-1н- бензимидазол-5-карбонил)пиридин-2-иламино]пропионовой кислоты и фармацевтическая композиция, которая его содержит | |
| ATE150014T1 (de) | Perhydroisoindol-derivate, deren herstellung und die sie behaltende pharmazeutische zusammenfassungen | |
| FR2731618B1 (fr) | Composition ophtalmique topique comprenant un derive de 2-(4-(azolylbutyl)-piperazinyl-methyl)-benzimidazole, notamment pour le traitement de la conjonctivite allergique |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |